The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of retreatment with sorafenib for metastatic renal cell carcinoma.
Masahiro Nozawa
No relevant relationships to disclose
Naoki Matsumura
No relevant relationships to disclose
Muneo Yasuda
No relevant relationships to disclose
Yasuto Okuda
No relevant relationships to disclose
Hirotsugu Uemura
No relevant relationships to disclose